Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zoetis ( (ZTS) ) has provided an update.
On February 5, 2026, Zoetis Inc.’s board of directors declared a second-quarter 2026 dividend of $0.53 per share, to be paid on June 2, 2026, to shareholders of record as of April 20, 2026, underscoring the company’s ongoing practice of returning cash to investors. The decision reflects Zoetis’s financial capacity to sustain shareholder distributions and may reinforce its appeal to income-focused investors within the animal health sector.
The most recent analyst rating on (ZTS) stock is a Hold with a $135.00 price target. To see the full list of analyst forecasts on Zoetis stock, see the ZTS Stock Forecast page.
Spark’s Take on ZTS Stock
According to Spark, TipRanks’ AI Analyst, ZTS is a Outperform.
Zoetis’ strong financial performance and strategic initiatives, such as share repurchases and dividend increases, are key strengths. However, technical indicators suggest a bearish trend, and challenges in certain market segments pose risks. Overall, the stock is well-positioned for growth, but investors should be mindful of market pressures.
To see Spark’s full report on ZTS stock, click here.
More about Zoetis
Zoetis Inc., a Fortune 500 company, is the world’s leading animal health business, focused on predicting, preventing, detecting and treating animal illness for veterinarians, pet owners and livestock producers. With a portfolio and pipeline of medicines, vaccines, diagnostics and technologies sold in more than 100 countries, Zoetis generated $9.3 billion in revenue in 2024 and employs approximately 13,800 people worldwide.
Average Trading Volume: 5,236,945
Technical Sentiment Signal: Sell
Current Market Cap: $55.84B
For an in-depth examination of ZTS stock, go to TipRanks’ Overview page.